Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA

被引：11

作者：

Grivas, Petros ^{[1
]}

DerSarkissian, Maral ^{[2
]}

Shenolikar, Rahul ^{[3
]}

Laliberte, Francois ^{[4
]}

Doleh, Yunes ^{[3
]}

Duh, Mei Sheng ^{[4
]}

机构：

[1] Univ Washington, Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

[2] Anal Grp Inc, Boston, MA 02199 USA

[3] AstraZeneca US, Gaithersburg, MD 20878 USA

[4] Grp Anal Ltee, Montreal, PQ H3B 0G7, Canada

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 33期

关键词：

bladder cancer; chemotherapy toxicity; health care costs; immunotherapy-related adverse events; urologic carcinoma; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; CARCINOMA; CHEMOTHERAPY; MULTICENTER; PEMBROLIZUMAB; ATEZOLIZUMAB; THERAPY; SAFETY;

D O I：

10.2217/fon-2019-0434

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To estimate incremental costs and healthcare resource utilization (HRU) associated with select severe adverse events (AEs) and AEs of any severity in patients with metastatic urothelial carcinoma receiving first-line (1L) therapy. Materials & methods: Adults treated with 1L systemic therapy between January 2012 and September 2017 with >= 1 urothelial cancer diagnosis were identified using claims data. Per-patient-per-month cost differences and HRU rate ratios comparing patients with and without select AEs were estimated. Results: Patients with any severe select AEs had higher costs than those without (cost difference = $6130 per-patient-per-month; p < 0.001). Healthcare costs and HRU for patients with select AEs were significantly higher versus those without. Conclusion: Select AEs during 1L therapy for metastatic urothelial carcinoma can result in significant burden to patients and healthcare systems.

引用

页码：3809 / 3818

页数：10

共 28 条

[1] Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma [J].

Aly, Abdalla ;

Johnson, Courtney ;

Yang, Shuo ;

Botteman, Marc F. ;

Rao, Sumati ;

Hussain, Arif .

JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (07) :662-670

[2]

*AM CANC SOC, 2019, KEY STAT BLADD CANC

[3]

*AM CANC SOC, 2017, SURV RAT BLADD CANC

[4] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[5] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[6] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[7] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[8]

CHU JN, 2018, J CLIN ONCOL S, V36

[9]

*GEN, 2019, TECENTRIQ AT HIGHL P

[10] Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting [J].

Hurvitz, Sara ;

Guerin, Annie ;

Brammer, Melissa ;

Guardino, Ellie ;

Zhou, Zheng-Yi ;

Viau, Dominick Latremouille ;

Wu, Eric Q. ;

Lalla, Deepa .

ONCOLOGIST, 2014, 19 (09) :901-908

← 1 2 3 →